65,437 trials
Cancer Cachexia
Primary: Change in Serum Albumin — 4.0 g/dL
Rheumatoid Arthritis
Primary: Proportion of Patients Meeting American College of Rheumatology 20 Response Criteria (ACR20) at 12weeks — 60; 56; 54 percent meeting ACR 20 — p=0.982
Myopia
Primary: Overall Vision Quality — 8.2; 8.7 units on a scale
Major Depression · Multiple Sclerosis · Amyotrophic Lateral Sclerosis
Primary: Hamilton Depression Scale (HAM-D 17). — 15 depression severity — p=0.01
Healthy
Primary: Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite. — 39.14; 30.01; 38.85; 29.33 ng/mL
Healthy
Primary: Cmax — 2567.9; 3568.9 ng/mL
Tic Disorders · Tourette Syndrome
Primary: Yale Global Tic Severity Scale (YGTSS): — 45.2; 48.7; 48.8; 43.1 scores on a scale
Cardiovascular Disease
Primary: Compare Change in Platelet Aggregation as Measured by Adenosine Diphosphate (ADP) Between PGJ and Placebo — 1.59; -12.3 percent
Fibromyalgia
Primary: Time to Loss of Therapeutic Response (LTR) — 56; NA Days — p=0.0004
Magnetic Resonance Imaging
Primary: Plasma Clearance Estimates of Gadobutrol by Age Group — 2.07; 3.28; 4.90; 3.24 L/h
Nausea and Vomiting of Pregnancy
Primary: Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall…
Stomach Neoplasms
Primary: Number of Participants With First-cycle Dose Limiting Toxicities (DLTs) — 1; 0; 3; 2 participants
Type 2 Diabetes Mellitus · Impaired Glucose Tolerance
Primary: Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks. — -0.06; -0.23; 0.04; 0.45 pmol/min/m^2/mmol/L
Metastatic Breast Cancer · Neoplasms, Breast
Primary: Clinical Benefit Response (Independent Reviewer-assessed) — 59 percentage of participants
Cerebral Infarction
Primary: The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study — 0.07…